Morgan Stanley analyst Sean Laaman maintained a Buy rating on Centessa Pharmaceuticals today and set a price target of $27.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sean Laaman has given his Buy rating due to a combination of factors that highlight Centessa Pharmaceuticals’ promising position in the market. The company’s ORX750 drug has demonstrated superior efficacy in recent trials compared to competitors, particularly in its ability to achieve a higher Maintenance of Wakefulness Test (MWT) score in a shorter treatment duration.
The emerging data suggests that ORX750 could be considered best-in-class within the orexin-2 landscape, especially given its well-tolerated profile and significant MWT outcomes. These factors, combined with the potential for ORX750 to perform well across various patient populations, underpin Laaman’s positive outlook on Centessa’s stock.
Laaman covers the Healthcare sector, focusing on stocks such as Neurocrine, Jazz Pharmaceuticals, and Exelixis. According to TipRanks, Laaman has an average return of 8.5% and a 61.35% success rate on recommended stocks.
In another report released on November 10, LifeSci Capital also maintained a Buy rating on the stock with a $49.00 price target.